As previously reported last night, Stifel initiated coverage of Zyus Life Sciences with a Speculative Buy rating and C$4 price target. Founder, President and CEO Brent Zettl has been pursuing drug commercialization using a cannabinoid formulation for 23 years and his previous endeavor culminated in “the largest takeover in the cannabis industry at the time,” notes the analyst. The firm believes Zyus’ lead drug candidate, Trichomylin, is “well positioned to offer investors an attractive risk/ reward opportunity” with a successful Phase 1 already completed and multiple data points suggesting efficacy, the analyst added.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TSE:ZYUS: